Ratings Kao Corporation OTC Markets

Equities

KAOOY

US4855374017

Market Closed - OTC Markets Other stock markets 20:47:34 28/06/2024 BST			5-day change	1st Jan Change
8.1 ^USD	-2.99%		-3.57%	-0.78%

06-28	Activist investor Oasis launches campaign against Japan drug store chain Ain	RE
06-10	Japan's Nikkei ends higher led by financials, export shares	RE

Summary

The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The company's profit outlook over the next few years is a strong asset.
Sales forecast by analysts have been recently revised upwards.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Over the past four months, analysts' average price target has been revised upwards significantly.
Analyst opinion has improved significantly over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 28.52 times its estimated earnings per share for the ongoing year.
The company appears highly valued given the size of its balance sheet.
The company is highly valued given the cash flows generated by its activity.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Personal Products

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
KAO CORPORATION	-0.78%	18.85B		-
L'ORÉAL	-9.01%	235B		B-
GALDERMA GROUP AG	0.00%	19.58B	-	-
SHISEIDO COMPANY, LIMITED	+7.90%	11.4B		A-
COTY INC.	-19.32%	8.65B		A-
AMOREPACIFIC CORPORATION	+15.38%	7.45B		B+
PROYA COSMETICS CO.,LTD.	+11.66%	6.03B		B
NATURA &CO HOLDING S.A.	-7.99%	3.87B		B+
INTER PARFUMS, INC.	-19.43%	3.72B		C-
KOSÉ CORPORATION	-3.22%	3.63B		B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes